Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sensei Biotherapeutics ( (SNSE) ) has provided an update.
On February 13, 2026, Sensei Biotherapeutics, Inc. expanded its board of directors from three to five members and appointed its President, Principal Executive Officer and General Counsel, Christopher W. Gerry, along with seasoned biopharma finance executive Phillip B. Donenberg, as new directors for terms lasting until their successors are elected and qualified. The appointments, which include standard director indemnification agreements and non-employee director compensation for Donenberg, strengthen the company’s governance with deep legal and financial expertise drawn from prior roles at AVROBIO, Taysha Gene Therapies, Jaguar Gene Therapy, Tectonic Therapeutic and other publicly traded life sciences companies, potentially enhancing oversight and strategic decision-making for stakeholders.
The most recent analyst rating on (SNSE) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.
Spark’s Take on SNSE Stock
According to Spark, TipRanks’ AI Analyst, SNSE is a Neutral.
The score is held down primarily by weak fundamentals—minimal/negative revenue, persistent losses, and ongoing cash burn with a shrinking equity base—implying continued financing risk. Technicals are a relative bright spot with price trading above key moving averages and positive MACD, but valuation remains constrained by negative earnings, and corporate events add uncertainty due to program discontinuation and strategic review.
To see Spark’s full report on SNSE stock, click here.
More about Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. is a biotechnology company operating in the life sciences sector, with a focus on developing innovative therapies. The company’s leadership includes executives with significant legal, financial and industry experience, reflecting its emphasis on robust corporate governance and strategic oversight in a competitive biopharmaceutical market.
Average Trading Volume: 88,109
Technical Sentiment Signal: Sell
Current Market Cap: $11.15M
See more data about SNSE stock on TipRanks’ Stock Analysis page.